JANX

Janux Therapeutics, Inc. (JANX) | Rumor.io

Janux Therapeutics

JANX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,786

Bullish sentiment (50-day avg)100%

Price to earnings ratio-9.07

Market capitalization1B

Earnings per share-1.67

Dividend yield (TTM)—

Revenue (annual)10M

Net income (annual)-113.6M

Social

What share of all stock conversation is about JANX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 23

Bristol Myers Squibb has partnered with Janux Therapeutics for up to $850M to develop masked tumor-activated T-cell engagers for solid tumors.
The deal includes up to $50M upfront and $800M in milestones plus tiered royalties, providing significant validation for Janux's "make T-cells safer" engineering.
Janux's tumor-activated platforms have been validated through this deal, which could be a game-changer for the company's solid tumor oncology focus.

Generated by AI

Sentiment

Of the messages about JANX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	57.27% -9.39
Bearish	—	—	0% 0	42.73% +9.39

Bullish· Jan 22

$JANX is already undervalued with a market cap of around $900M despite having $1B in cash and a robust pipeline.
The company's partnership with BMS and M&A validation from $BMY demonstrate its potential for future revenues and milestone payments.
The stock's low float, high short interest, and undervalued cash position make it a prime candidate for a significant price increase.

Bearish· Jan 22

$JANX is trading below its actual cash on hand, making it a no-brainer short.
The company's valuation is a "disgrace and joke" compared to its peers, with only 3 out of 216 biotechs valued under 1x cash.
$JANX's enterprise value is still negative, making it an "easy buy" for the long term.

Generated by AI

Topics

Of the messages about JANX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	38.36%
Analysts	—	—	—	28.65%
Controversies	—	—	—	0.05%
Earnings	—	—	—	19.1%
Macro	—	—	—	3.5%
Technical Analysis	—	—	—	10.33%

Analysts· Dec 2

Cantor Fitzgerald has adjusted their stance on Janux Therapeutics ( $JANX ), setting the rating to Overweight with a target price of 150, citing the drug's overall effectiveness weakened on certain key measures, but still a "show me" story.
Analysts updates all high 30s to mid 40s, with C. H. Wainwright reducing its price target to $45 from $70 and maintained a 'Buy' rating, and Bank of America Securities cutting its target to $49 from $58 and keeping a 'Buy'.
Analysts are affirming their Buy ratings on Janux Therapeutics, with Stifel updates rating for Janux Therapeutics ( $JANX ) to Buy, target set at 46 → 38, and Phipps from Clear Street maintaining a Buy rating with a target price of 80 → 32.

Announcements· Jan 22

Janux Therapeutics, Inc. (JANX) announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors.
The partnership has the potential to generate up to $850 million in payments for Janux, including upfront and near-term milestone payments, as well as development, regulatory, and commercial milestones.
The deal is seen as a validation of Janux's platform and may trigger institutional re-rating, with big pharma partnering only when the science checks out, and momentum likely sticking if volume confirms.

Generated by AI

Community

Of the messages about JANX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	12.5%	24.64%
Newcomers	—	—	87.5%	75.36%

Jan 22

The collaboration between Janux Therapeutics and Bristol Myers Squibb has the potential to drive significant growth for Janux, with a 900 million dollar cash infusion and reasonable R&D spend.
The deal between Janux and Bristol Myers Squibb is expected to lead to a new therapeutic for solid tumors, which could be a major catalyst for the stock.
The partnership has already shown positive momentum, with a 6.1% increase in the stock price and a significant increase in sales and EPS.

Generated by AI

Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the near term, with a 1-month share price return down 9.6% and a 7-day move down 1.75%, even as the 90-day share price return is up 6.36% and the year-to-date share price return stands at 19.41%. Over a...

2d agoYahoo Finance

Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed (JANX)

11d agoSeeking Alpha

Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow (NASDAQ:JANX) 2026-09-17

12d agoSeeking Alpha

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux

Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

14d agoYahoo Finance

Janux doses first patient in JANX013 prostate cancer trial

15d agoInvesting.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

SAN DIEGO, September 14, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).

15d agoYahoo Finance Australia

Also Discussed

Investors talking about JANX also mention

#	Name	Attention
1	Cullinan Therapeutics Inc.CGEM	0%new
2	Nuvalent, Inc.NUVL	0%0
3	ETNB - 89bio, Inc.	——
4	Vir Biotechnology, Inc.VIR	0%+0
5	IDEAYA Biosciences Inc.IDYA	0%-0.01
6	CytomX Therapeutics, Inc.CTMX	0%0
7	Apogee Therapeutics, Inc. - Common StockAPGE	0%0
8	SWTX - SpringWorks Therapeutics, Inc.	——
9	DAWN - Day One Biopharmaceuticals, Inc.	——
10	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new

Janux Therapeutics, Inc.

Healthcare
Biotechnology

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for cancer. The company’s core programs are built around its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, which are designed to activate immune responses selectively in tumors while limiting effects on healthy tissue. Janux Therapeutics is advancing a pipeline of investigational candidates that target a range of cancers, including solid tumors and prostate cancer, and its research also extends to autoimmune disease applications. The company works through preclinical and early clinical development activities, supported by collaboration and discovery efforts, positioning it as a platform-driven biotechnology business centered on novel immune-oncology research.

Website

Location

10955 Vista Sorrento Parkway

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about JANX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 23

Bristol Myers Squibb has partnered with Janux Therapeutics for up to $850M to develop masked tumor-activated T-cell engagers for solid tumors.
The deal includes up to $50M upfront and $800M in milestones plus tiered royalties, providing significant validation for Janux's "make T-cells safer" engineering.
Janux's tumor-activated platforms have been validated through this deal, which could be a game-changer for the company's solid tumor oncology focus.

Generated by AI

Sentiment

Of the messages about JANX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	57.27% -9.39
Bearish	—	—	0% 0	42.73% +9.39

Bullish· Jan 22

$JANX is already undervalued with a market cap of around $900M despite having $1B in cash and a robust pipeline.
The company's partnership with BMS and M&A validation from $BMY demonstrate its potential for future revenues and milestone payments.
The stock's low float, high short interest, and undervalued cash position make it a prime candidate for a significant price increase.

Bearish· Jan 22

$JANX is trading below its actual cash on hand, making it a no-brainer short.
The company's valuation is a "disgrace and joke" compared to its peers, with only 3 out of 216 biotechs valued under 1x cash.
$JANX's enterprise value is still negative, making it an "easy buy" for the long term.

Generated by AI

Topics

Of the messages about JANX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	38.36%
Analysts	—	—	—	28.65%
Controversies	—	—	—	0.05%
Earnings	—	—	—	19.1%
Macro	—	—	—	3.5%
Technical Analysis	—	—	—	10.33%

Analysts· Dec 2

Cantor Fitzgerald has adjusted their stance on Janux Therapeutics ( $JANX ), setting the rating to Overweight with a target price of 150, citing the drug's overall effectiveness weakened on certain key measures, but still a "show me" story.
Analysts updates all high 30s to mid 40s, with C. H. Wainwright reducing its price target to $45 from $70 and maintained a 'Buy' rating, and Bank of America Securities cutting its target to $49 from $58 and keeping a 'Buy'.
Analysts are affirming their Buy ratings on Janux Therapeutics, with Stifel updates rating for Janux Therapeutics ( $JANX ) to Buy, target set at 46 → 38, and Phipps from Clear Street maintaining a Buy rating with a target price of 80 → 32.

Announcements· Jan 22

Janux Therapeutics, Inc. (JANX) announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors.
The partnership has the potential to generate up to $850 million in payments for Janux, including upfront and near-term milestone payments, as well as development, regulatory, and commercial milestones.
The deal is seen as a validation of Janux's platform and may trigger institutional re-rating, with big pharma partnering only when the science checks out, and momentum likely sticking if volume confirms.

Generated by AI

Community

Of the messages about JANX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	12.5%	24.64%
Newcomers	—	—	87.5%	75.36%

Jan 22

The collaboration between Janux Therapeutics and Bristol Myers Squibb has the potential to drive significant growth for Janux, with a 900 million dollar cash infusion and reasonable R&D spend.
The deal between Janux and Bristol Myers Squibb is expected to lead to a new therapeutic for solid tumors, which could be a major catalyst for the stock.
The partnership has already shown positive momentum, with a 6.1% increase in the stock price and a significant increase in sales and EPS.

Generated by AI

Janux Therapeutics

Social

Jan 23

Sentiment

Bullish· Jan 22

Bearish· Jan 22

Topics

Analysts· Dec 2

Announcements· Jan 22

Community

Jan 22

News

Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey

Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed (JANX)

Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow (NASDAQ:JANX) 2026-09-17

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux

Janux doses first patient in JANX013 prostate cancer trial

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

Also Discussed

Janux Therapeutics, Inc.

Company Information

Location

News

Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey

Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed (JANX)

Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow (NASDAQ:JANX) 2026-09-17

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux

Janux doses first patient in JANX013 prostate cancer trial

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

Also Discussed

Social

Jan 23

Sentiment

Bullish· Jan 22

Bearish· Jan 22

Topics

Analysts· Dec 2

Announcements· Jan 22

Community

Jan 22